Acquistion expands Optibrium's 3D drug design and visualisation software
Optibrium has announced the acquisition of BioPharmics, expanding its 3D drug design and modelling services. Bringing decades of experience in computational chemistry and biology, BioPharmics’ CEO, Dr Ajay Jain, and Director of Applied Science, Dr Ann Cleves, join the Optibrium team, respectively focusing on R&D and Application Science in the newly-created BioPharmics Division.
BioPharmics has developed a series of algorithms and software for 3D ligand-based and structure-based computational drug design, including software for 2D to 3D ligand conversion and conformer generation (ForceGen), molecular docking (Surflex-Dock), molecular similarity (eSim), and binding affinity prediction (QuanSA). These highly performant products have all been rigorously researched and their results demonstrated in numerous peer-reviewed papers, many published jointly with key pharmaceutical industry partners.
Dr Matthew Segall, CEO, Optibrium said stated: “After years of close collaboration, we are delighted that Optibrium was chosen to support BioPharmics’ continued scientific innovation and expanding customer base. We are delighted to welcome Ajay and Ann to the team. Their extensive experience in computational chemistry and biology, alongside BioPharmics’ world-leading software for 3D ligand- and structure-based design, will bring Optibrium to the forefront of these essential technologies for small molecule discovery and design.”
The strategic acquisition brings powerful technology for 3D ligand- and structure-based design into Optibrium's comprehensive StarDrop platform for small molecule design, optimisation and data analysis, complementing its existing range of artificial intelligence, de novo design, and in silico modelling software. The deal follows a long-standing collaboration between the two companies, including partnering on developing the Surflex eSim3D StarDrop module.
In their new roles, Ajay and Ann will continue the research and application of novel methods to extend the application of 3D modelling to traditional small molecules, as well as to beyond Rule-of-Five compounds that are becoming increasingly prevalent in drug discovery.
Ajay has over 30 years of experience working in the field of computer-aided drug design (CADD). Prior to founding BioPharmics, he held a series of senior scientific roles in multiple small biopharma companies, including Arris Pharmaceuticals, MetaXen, and Iconix Pharmaceuticals. He was also faculty at the University of California, San Francisco (UCSF) for over two decades, with a broad research program encompassing genomics and cancer genetics, in addition to CADD. Ajay holds a PhD in Computer Science from Carnegie Mellon University.
Ann brings extensive expertise in applied research in computational chemistry and biology, and in the relationship between molecular structure and pharmacology, gained through her long tenure both within academic and biopharmaceutical settings. Ann and Ajay began their collaboration at MetaXen, which then continued at UCSF, and she has been an integral part of BioPharmics for many years. Ann holds a PhD in Microbiology and Cell Biology from the University of Illinois.
Dr Ajay Jain, Founder and CEO of BioPharmics, commented: “We have always been impressed by Optibrium’s focus on scientific rigour, and we firmly believe that there is no better team to continue the powerful software developments that BioPharmics has introduced over the years. I look forward to working as part of the Optibrium team to expand their internal expertise in 3D drug design, as well as on future drug discovery innovations.”
Dr Ann Cleves, Director of Applied Science at BioPharmics, added: “We have enjoyed working with Optibrium over the years, and the high levels of mutual respect for the scientific expertise from each side of the partnership has enabled this next step. I am excited to see the new products and ground-breaking science that we will deliver together.”